Industry Treatment News
This page lists treatment news from IFFGD Industry Council Members. No endorsement is intended or implied.
What's in the news
January 5, 2015 – The Japanese Ministry of Health, Labor, and Welfare (MHLW) granted teduglutide (Gattex in the US; Revestive in the EU) orphan drug status for the treatment of adult patients with short bowel syndrome (SBS). Learn more
CSID Genetic Prevalence Study
October 8, 2014 – Participants aged 18 or younger are being sought for a research study that could help your child and others who are experiencing chronic diarrhea and/or abdominal pain due to a possible deficiency in table sugar digestion. Learn more
September 28, 2014 – The U.S. Food and Drug Administration (FDA) approved an expanded use of the drug, Relistor, for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
September 19, 2014 – The supplemental new drug application (sNDA) for the antibiotic, rifaximin 550 mg, has been accepted for review by the U.S. Food & Drug Administration (FDA) for treating patients with irritable bowel syndrome with diarrhea (IBS-D). Learn more
September 2, 2014 – The U.S. Food & Drug Administration (FDA) has granted priority review status to the new Drug Application (NDA) for eluxadoline, an investigational drug for the treatment of diarrhea predominant irritable bowel syndrome (IBS-D) in men and women. Learn more
August 21, 2014 – Research studies suggest that nutritional therapy with SBI, the ingredient found in EnteraGam – used in addition to traditional medical care – can help manage various symptoms associated intestinal disease (enteropathy) like irritable bowel syndrome with diarrhea (IBS-D). Learn more
June 30, 2014 – The U.S. Food and Drug Administration (FDA) has approved updated labeling for Gattex (teduglutide [rDNA origin]) for injection, to include long-term data from adult patients with Short Bowel Syndrome (SBS). Learn more
May 27, 2014 – An article published in the journal Therapeutic Advances in Gastroenterology reviewed data that examined the mechanisms by which bile acids can affect symptoms in chronic idiopathic constipation (CIC) and the role of the drug elobixibat in managing these symptoms. Learn more
May 6, 2014 – A study published in the medical journal Pain Medicine concluded that lubiprostone effectively relieved symptoms of opioid-induced constipation (OIC) and associated signs and symptoms. Learn more
April 22, 2014 – Salix announced that their submission for the medication Relistor had been accepted for review by the European Medicines Agency. Their submission asks to allow the use of Relistor for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The European Union already allows for the use of Relistor in patients with advanced illness.
June 13, 2013 – Linaclotide is now available in Europe (branded as Costella in the EU) to treat irritable bowel syndrome with constipation (IBS-C). Learn more
September 6, 2011 – Oceana Therapeutics today announced the U.S. launch of Solesta, a significant new treatment option for patients with fecal (bowel) incontinence for whom conservative therapies have failed. Learn more
September 8, 2009 – The FDA has granted marketing approval for the drug metoclopramide (Metozolv) 5mg and 10 mg orally disintegrating tablets. The drug is indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults and the treatment of symptomatic documented GERD in adults who do not respond to conventional therapy. Therapy should not exceed 12 weeks in duration. Important safety information should be discussed with your doctor. Learn more
January 30, 2009 – The U.S. Food and Drug Administration (FDA) today approved KAPIDEX™ (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. KAPIDEX (30 mg and 60 mg) is the first proton pump inhibitor (PPI) with a Dual Delayed Release™ (DDR) formulation designed to provide two separate releases of medication. Learn more
Kapidex changed its name to Dexilant in April 2010.